3-氯甲基-5-(3,5-二甲基异噁唑-4-基)-1,2,4-噁二唑 | 175205-42-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 3-氯甲基-5-(3,5-二甲基异噁唑-4-基)-1,2,4-噁二唑
• 中文别名: 3-氯甲基-5-(3,5-二甲基异恶唑-4-基)-1,2,4-氧二唑
• 英文名称: 3-(chloromethyl)-5-(3,5-dimethyl-4-isoxazolyl)-1,2,4-oxadiazole
• 英文别名: 3-(chloromethyl)-5-(3,5,-dimethylisoxazol-4-yl)-1,2,4-oxadiazole；3-(Chloromethyl)-5-(3,5-dimethylisoxazol-4-yl)-1,2,4-oxadiazole；3-(chloromethyl)-5-(3,5-dimethyl-1,2-oxazol-4-yl)-1,2,4-oxadiazole
• CAS: 175205-42-2
• 化学式: C₈H₈ClN₃O₂
• mdl: MFCD00052098
• 分子量: 213.623
• InChiKey: UBNGKQCKUVRCGR-UHFFFAOYSA-N

物化性质

• 熔点：
  88 °C
• 沸点：
  374.0±52.0 °C(Predicted)
• 密度：
  1.333±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.375
• 拓扑面积：
  65
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 危险品标志：
  C
• 安全说明：
  S26
• 危险类别码：
  R34
• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  3-氯甲基-5-(3,5-二甲基异噁唑-4-基)-1,2,4-噁二唑 生成 4-({[5-(3,5-dimethyl-4-isoxazolyl)-1,2,4-oxadiazol-3-yl]methyl}sulfonyl)phenethylamine
  参考文献：
  名称：

  Substituted arylsulfides, arylsulfoxides and arylsulfones as beta-3 adrenergic receptor agonists

  摘要：

  本发明提供了具有以下结构式的I型化合物： 1 其中R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , Y, Z, m, n, 2 以及前述定义的 pharmaceutically acceptable salt，它们在治疗或抑制与胰岛素抵抗或高血糖相关的代谢紊乱（通常与肥胖或葡萄糖不耐受有关）、动脉粥样硬化、胃肠疾病、神经源性炎症、青光眼、眼压升高和频繁排尿方面非常有用；它们在治疗或抑制2型糖尿病方面特别有用。

  公开号：

  US20020040023A1

文献信息

• Alpha-helical mimetics
  申请人：Lessene Guillaume Laurent

  公开号：US20080153802A1

  公开（公告）日：2008-06-26

  Benzoyl urea derivatives that are alpha helical peptides mimetics that mimic BH3-only proteins, compositions containing them, their conjugation to cell-targeting-moieties, and their use in the regulation of cell death are disclosed. The benzoyl urea derivatives are capable of binding to and neutralizing pro-survival Bcl-2 proteins. Use of benzoyl urea derivatives in the treatment and/or prophylaxis of diseases or conditions associated with deregulation of cell death are also described.

  公开了模拟α螺旋肽的苯甲酰脲衍生物，这些衍生物模拟BH3-仅蛋白，含有它们的组合物，它们与细胞靶向基团的结合，以及它们在调节细胞死亡中的用途。苯甲酰脲衍生物能够结合并中和促生存的Bcl-2蛋白。还描述了在治疗和/或预防与细胞死亡失调相关的疾病或症状中使用苯甲酰脲衍生物。
• Inhibitors of aspartyl protease
  申请人：Vertex Pharmaceuticals Incorporated.

  公开号：US20040122000A1

  公开（公告）日：2004-06-24

  The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.

  本发明涉及一类新型磺胺类化合物，其为天冬氨酸蛋白酶抑制剂。在一个实施例中，本发明涉及一类新型HIV天冬氨酸蛋白酶抑制剂，其具有特定的结构和理化特征。本发明还涉及包含这些化合物的药物组合物。本发明的化合物和药物组合物特别适用于抑制HIV-1和HIV-2蛋白酶活性，因此，可以有利地用作抗HIV-1和HIV-2病毒的抗病毒剂。本发明还涉及使用本发明的化合物抑制HIV天冬氨酸蛋白酶活性的方法以及筛选具有抗HIV活性的化合物的方法。
• Thiazole compounds and pharmaceutical compositions for inhibiting protein kinases and methods for their use
  申请人：Agouron Pharmaceuticals, Inc.

  公开号：US20020025976A1

  公开（公告）日：2002-02-28

  Diaminothiazole compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction in order to modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.

  二氨基噻唑化合物可调节和/或抑制特定蛋白激酶的活性。这些化合物及含有它们的药物组合物能够介导酪氨酸激酶信号传导，以调节和/或抑制不需要的细胞增殖。本发明还涉及含有这些化合物的药物组合物的治疗或预防用途，以及通过给予这些化合物的有效量来治疗癌症以及与不需要的血管生成和/或细胞增殖相关的其他疾病状态，如糖尿病视网膜病变、新生血管性青光眼、类风湿性关节炎和牛皮癣的方法。
• IMIDAZOLE DERIVATIVES AS INHIBITORS OF TAFIA
  申请人：KALLUS Christopher

  公开号：US20080262028A1

  公开（公告）日：2008-10-23

  The present invention is directed to a compound of formula I: or any stereoisomeric form of the compound of the formula I or a mixture of these forms in any ratio or a physiologically acceptable salt of the compound of the formula I which inhibit the enzyme TAFIa (activated thrombin-activatable fibrinolysis inhibitor), and to a process for their preparation and to their use to treat described diseases where the substituents are as described in the specification.

  本发明涉及一种式I化合物： 或式I化合物的任何立体异构体形式，或这些形式的任何比例的混合物，或式I化合物的生理可接受盐，该化合物抑制酶TAFIa（活化的凝血酶可激活的纤维蛋白溶解抑制剂），以及涉及它们的制备方法及其用于治疗说明书中所述疾病的使用，其中取代基如说明书中所述。
• Chemical Compounds
  申请人：Turnbull Philip Stewart

  公开号：US20090170907A1

  公开（公告）日：2009-07-02

  This invention relates to non-steroidal compounds that are modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors, and also to the methods for the making and use of such compounds.

  这项发明涉及非甾体化合物，它们是雄激素、糖皮质激素、矿质皮质激素和孕激素受体的调节剂，以及这些化合物的制备和使用方法。